Pata Francesco, Bracchitta Luigi Maria, D'Ambrosio Giancarlo, Bracchitta Salvatore
Department of Surgery, Nicola Giannettasio Hospital, 87064 Corigliano-Rossano, Italy.
La Sapienza University, 00185 Rome, Italy.
J Clin Med. 2021 Dec 31;11(1):218. doi: 10.3390/jcm11010218.
Sclerobanding is a novel technique combining rubber band ligation with 3% polidocanol foam sclerotherapy for the treatment of hemorrhoidal disease (HD). The aim of this study is to evaluate the feasibility, safety and short-term outcomes of sclerobanding in the treatment of second- and third-degree HD.
A retrospective analysis of second- and third-degree HD cases from November 2017 to August 2021 was performed. Patients on anticoagulants or with other HD degrees were excluded. Follow-up was conducted at 1 month, 3 months, 6 months, 1 year and then every 12 months.
97 patients with second- (20 pts; 20.6%) and third-degree (77 pts; 79.4%) HD with a mean age of 52 years (20-84; SD ± 15.5) were included. Fifty-six patients were men (57.7%) and forty-one women (42.3%). Median follow-up was 13 months (1-26 months). No intraoperative adverse events or drug-related side effects occurred. Minor complications occurred in four patients (4.1%) in the first 30 postoperative days and all resolved after conservative treatment at the 3-month follow-up visit. No mortality or readmissions were observed.
Sclerobanding is a safe technique with a low rate of minor postoperative complications. Further studies on larger samples are necessary to establish the effectiveness and long-term outcomes of the technique.
硬化套扎术是一种将橡皮筋结扎术与3%聚多卡醇泡沫硬化疗法相结合的新技术，用于治疗痔病（HD）。本研究的目的是评估硬化套扎术治疗二度和三度HD的可行性、安全性和短期疗效。
对2017年11月至2021年8月的二度和三度HD病例进行回顾性分析。排除正在接受抗凝治疗或患有其他HD程度的患者。在1个月、3个月、6个月、1年，然后每12个月进行一次随访。
纳入97例二度（20例；20.6%）和三度（77例；79.4%）HD患者，平均年龄52岁（20 - 84岁；标准差±15.5）。56例为男性（57.7%），41例为女性（42.3%）。中位随访时间为13个月（1 - 26个月）。未发生术中不良事件或药物相关副作用。4例患者（4.1%）在术后30天内出现轻微并发症，在3个月随访时经保守治疗后均痊愈。未观察到死亡或再次入院情况。
硬化套扎术是一种安全的技术，术后轻微并发症发生率低。需要对更大样本进行进一步研究，以确定该技术的有效性和长期疗效。
